Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEEPsAKE 2: risankizumab versus placebo in active psoriatic arthritis
2023-505477-33-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) and plaque psoriasis comparing Risankizumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Planned start Jun 2019; status: authorised.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on 2023-505477-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505477-33-00.